MTOR and neuroendocrine neoplasm: A subgroup analysis showed that PI3K/AKT/mTOR pathway inhibitor-based therapies improved the OS of the patients with breast cancer, renal cancer, gastrointestinal cancer, head and neck squamous cell cancer, pancreatic cancer, neuroendocrine tumour and sarcomas but the differences were not statistically.